Treatment with ginger ameliorates fructose-induced fatty liver and hypertriglyceridemia in rats: Modulation of the hepatic carbohydrate response element-binding protein-mediated pathway

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Gao, Huanqing ^a   Guan, Tao ^a   Li, Chunli ^a   Zuo, Guowei ^a   Yamahara, Johji ^b   Wang, Jianwei ^a   Li, Yuhao ^c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Pharmafood Institute   (Japan)

^c Sydney Institute of Health Sciences   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; FATTY ACID; FRUCTOSE; GINGER EXTRACT; GLUCOSE; LIVER TRIACYLGLYCEROL LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL VACUOLE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; FATTY LIVER; GENE EXPRESSION; GENE OVEREXPRESSION; GINGER; HISTOPATHOLOGY; HYPERTRIGLYCERIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

EID: 84870223869     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/570948     Document Type: Article

References (49)

1. Nicoll R., Henein M. Y., Ginger (Zingiber officinale Roscoe): a hot remedy for cardiovascular disease? International Journal of Cardiology 2009 131 3 408 409 2-s2.0-58149204183 10.1016/j.ijcard.2007.07.107
2. Ali B. H., Blunden G., Tanira M. O., Nemmar A., Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food and Chemical Toxicology 2008 46 2 409 420 2-s2.0-37349127807 10.1016/j.fct.2007.09.085 (Pubitemid 350297543)
3. Bhandari U., Sharma J. N., Zafar R., The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits. Journal of Ethnopharmacology 1998 61 2 167 171 2-s2.0-0032101966 10.1016/S0378-8741(98) 00026-9 (Pubitemid 28297907)
4. Fuhrman B., Rosenblat M., Hayek T., Coleman R., Aviram M., Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. Journal of Nutrition 2000 130 5 1124 1131 2-s2.0-0034011401 (Pubitemid 30233257)
5. Kadnur S. V., Goyal R. K., Beneficial effects of Zingiber officinale Roscoe on fructose induced hyperlipidemia and hyperinsulinemia in rats. Indian Journal of Experimental Biology 2005 43 12 1161 1164 2-s2.0-28844458471 (Pubitemid 41769216)
6. Al-Amin Z. M., Thomson M., Al-Qattan K. K., Ali M., Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. British Journal of Nutrition 2006 96 4 660 666 2-s2.0-33947274715 10.1079/BJN20061849 (Pubitemid 46470189)
7. Nammi S., Sreemantula S., Roufogalis B. D., Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic and Clinical Pharmacology and Toxicology 2009 104 5 366 373 2-s2.0-64549145497 10.1111/j.1742-7843.2008.00362. x
8. Nammi S., Kim M. S., Gavande N. S., Li G. Q., Roufogalis B. D., Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase expression by Zingiber officinale in the liver of high-fat diet-fed rats. Basic and Clinical Pharmacology and Toxicology 2010 106 5 389 395 2-s2.0-77951073882 10.1111/j.1742-7843.2009.00497.x
9. Beattie J. H., Nicol F., Gordon M.-J., Reid M. D., Cantlay L., Horgan G. W., Kwun I.-S., Ahn J.-Y., Ha T.-Y., Ginger phytochemicals mitigate the obesogenic effects of a high-fat diet in mice: a proteomic and biomarker network analysis. Molecular Nutrition and Food Research 2011 55 supplement S203 S213 2-s2.0-80053289637 10.1002/mnfr.201100193
10. Johnson R. J., Perez-Pozo S. E., Sautin Y. Y., Manitius J., Sanchez-Lozada L. G., Feig D. I., Shafiu M., Segal M., Glassock R. J., Shimada M., Roncal C., Nakagawa T., Hypothesis: Could excessive fructose intake and uric acid cause type 2 diabetes? Endocrine Reviews 2009 30 1 96 116 2-s2.0-60549110854 10.1210/er.2008-0033
11. Stanhope K. L., Schwarz J. M., Keim N. L., Griffen S. C., Bremer A. A., Graham J. L., Hatcher B., Cox C. L., Dyachenko A., Zhang W., McGahan J. P., Seibert A., Krauss R. M., Chiu S., Schaefer E. J., Ai M., Otokozawa S., Nakajima K., Nakano T., Beysen C., Hellerstein M. K., Berglund L., Havel P. J., Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation 2009 119 5 1322 1334 2-s2.0-66449093225 10.1172/JCI37385
12. Tappy L., Lê K. A., Metabolic effects of fructose and the worldwide increase in obesity. Physiological Reviews 2010 90 1 23 46 2-s2.0-75149166672 10.1152/physrev.00019.2009
13. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 4 917 923 2-s2.0-0037382786 10.1053/jhep.2003.50161 (Pubitemid 36397405)
14. Postic C., Girard J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation 2008 118 3 829 838 2-s2.0-40549135297 10.1172/JCI34275 (Pubitemid 351364588)
15. Abdelmalek M. F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R. J., Diehl A. M., Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010 51 6 1961 1971 2-s2.0-77952692915 10.1002/hep.23535
16. Brunzell J. D., Hypertriglyceridemia. New England Journal of Medicine 2007 357 10 1009 1017 2-s2.0-34548433987 10.1056/NEJMcp070061 (Pubitemid 47367080)
17. Rong X., Peng G., Suzuki T., Yang Q., Yamahara J., Li Y., A 35-day gavage safety assessment of ginger in rats. Regulatory Toxicology and Pharmacology 2009 54 2 118 123 2-s2.0-67349189944 10.1016/j.yrtph.2009.03.002
18. Roglans N., Vilà L., Farré M., Alegret M., Sánchez R. M., Vázquez-Carrera M., Laguna J. C., Impairment of hepatic STAT-3 activation and reduction of PPAR α activity in fructose-fed rats. Hepatology 2007 45 3 778 788 2-s2.0-33947384599 10.1002/hep.21499 (Pubitemid 46450629)
19. Huang X. S., Zhao S. P., Bai L., Hu M., Zhao W., Zhang Q., Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor- α British Journal of Pharmacology 2009 158 3 706 712 2-s2.0-70350062074 10.1111/j.1476-5381.2009.00350.x
20. Roglans N., Sanguino E., Peris C., Alegret M., Vázquez M., Adzet T., Díaz C., Hernández G., Laguna J. C., Sánchez R. M., Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. Journal of Pharmacology and Experimental Therapeutics 2002 302 1 232 239 2-s2.0-0036082627 10.1124/jpet.302.1.232 (Pubitemid 34680443)
21. Rong X., Li Y., Ebihara K., Zhao M., Naowaboot J., Kusakabe T., Kuwahara K., Murray M., Nakao K., Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia 2010 53 8 1727 1731 2-s2.0-77955512722 10.1007/s00125-010-1744-6
22. Denechaud P. D., Dentin R., Girard J., Postic C., Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Letters 2008 582 1 68 73 2-s2.0-37349081571 10.1016/j.febslet.2007.07.084 (Pubitemid 350297238)
23. Postic C., Dentin R., Denechaud P. D., Girard J., ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annual Review of Nutrition 2007 27 179 192 2-s2.0-38449087713 10.1146/annurev.nutr.27.061406. 093618 (Pubitemid 351373354)
24. Dentin R., Benhamed F., Hainault I., Fauveau V., Foufelle F., Dyck J. R. B., Girard J., Postic C., Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006 55 8 2159 2170 2-s2.0-33749370739 10.2337/db06-0200 (Pubitemid 44743612)
25. Iizuka K., Miller B., Uyeda K., Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. American Journal of Physiology 2006 291 2 E358 E364 2-s2.0-33745896223 10.1152/ajpendo.00027.2006 (Pubitemid 44043073)
26. Uyeda K., Repa J. J., Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metabolism 2006 4 2 107 110 2-s2.0-33746536677 10.1016/j.cmet.2006.06.008 (Pubitemid 44138720)
27. Koo H. Y., Miyashita M., Simon Cho B. H., Nakamura M. T., Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochemical and Biophysical Research Communications 2009 390 2 285 289 2-s2.0-70350131993 10.1016/j.bbrc.2009.09.109
28. Rodríguez-Calvo R., Barroso E., Serrano L., Coll T., Sánchez R. M., Merlos M., Palomer X., Laguna J. C., Vázquez- Carrera M., Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009 49 1 106 115 2-s2.0-58949094416 10.1002/hep.22570
29. Mori T., Kondo H., Hase T., Murase T., Dietary phospholipids ameliorate fructose-induced hepatic lipid and metabolic abnormalities in rats. Journal of Nutrition 2011 141 11 2003 2009 2-s2.0-81055126867 10.3945/jn.111.143602
30. Evans R. M., Barish G. D., Wang Y. X., PPARs and the complex journey to obesity. Nature Medicine 2004 10 4 355 361 2-s2.0-1942518840 10.1038/nm1025 (Pubitemid 38508511)
31. Chao L., Marcus-Samuels B., Mason M. M., Moitra J., Vinson C., Arioglu E., Gavrilova O., Reitman M. L., Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. Journal of Clinical Investigation 2000 106 10 1221 1228 2-s2.0-0033708410
32. Gavrilova O., Haluzik M., Matsusue K., Cutson J. J., Johnson L., Dietz K. R., Nicol C. J., Vinson C., Gonzalez F. J., Reitman M. L., Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry 2003 278 36 34268 34276 2-s2.0-0141446024 10.1074/jbc.M300043200 (Pubitemid 37553270)
33. Kang S. A., Hong K., Jang K. H., Kim Y. Y., Choue R., Lim Y., Altered mRNA expression of hepatic lipogenic enzyme and PPAR α in rats fed dietary levan from Zymomonas mobilis. Journal of Nutritional Biochemistry 2006 17 6 419 426 2-s2.0-33646569970 10.1016/j.jnutbio.2005.08.012 (Pubitemid 43729352)
34. Sharma A. K., Bharti S., Ojha S., Bhatia J., Kumar N., Ray R., Kumari S., Arya D. S., Up-regulation of PPAR γ heat shock protein-27 and -72 by naringin attenuates insulin resistance, β -cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. British Journal of Nutrition 2011 106 11 1713 1723 2-s2.0-82255195245 10.1017/S000711451100225X
35. Xu K. Z. Y., Zhu C., Kim M. S., Yamahara J., Li Y., Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. Journal of Ethnopharmacology 2009 123 2 280 287 2-s2.0-67349248083 10.1016/j.jep.2009.03.035
36. Isa Y., Miyakawa Y., Yanagisawa M., Goto T., Kang M. S., Kawada T., Morimitsu Y., Kubota K., Tsuda T., 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF- α mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 2008 373 3 429 434 2-s2.0-47249108459 10.1016/j.bbrc.2008.06.046
37. Lefebvre P., Chinetti G., Fruchart J. C., Staels B., Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. Journal of Clinical Investigation 2006 116 3 571 580 2-s2.0-33644652183 10.1172/JCI27989 (Pubitemid 43326861)
38. Nagai Y., Nishio Y., Nakamura T., Maegawa H., Kikkawa R., Kashiwagi A., Amelioration of high fructose-induced metabolic derangements by activation of PPAR α American Journal of Physiology 2002 282 5 E1180 E1190 2-s2.0-0036084269 (Pubitemid 34654734)
39. Qu S., Su D., Altomonte J., Kamagate A., He J., Perdomo G., Tse T., Jiang Y., Dong H. H., PPAR α mediates the hypolipidemic action of fibrates by antagonizing FoxO1. American Journal of Physiology 2007 292 2 E421 E434 2-s2.0-33846878069 10.1152/ajpendo.00157.2006 (Pubitemid 46220566)
40. Yokozawa T., Hyun J. K., Eun J. C., Gravinol ameliorates high-fructose-induced metabolic syndrome through regulation of lipid metabolism and proinflammatory state in rats. Journal of Agricultural and Food Chemistry 2008 56 13 5026 5032 2-s2.0-47849122702 10.1021/jf800213f (Pubitemid 352039100)
41. Kim H. Y., Okubo T., Juneja L. R., Yokozawa T., The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. British Journal of Nutrition 2010 103 4 502 512 2-s2.0-77649210755 10.1017/S0007114509991978
42. Oosterveer M. H., Grefhorst A., van Dijk T. H., Havinga R., Staels B., Kuipers F., Groen A. K., Reijngoud D. J., Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. Journal of Biological Chemistry 2009 284 49 34036 34044 2-s2.0-71749090862 10.1074/jbc.M109.051052
43. Bijland S., Pieterman E. J., Maas A. C. E., Van Der Hoorn J. W. A., Van Erk M. J., Van Klinken J. B., Havekes L. M., Van Dijk K. W., Princen H. M. G., Rensen P. C. N., Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE3-Leiden.CETP mice. Journal of Biological Chemistry 2010 285 33 25168 25175 2-s2.0-77955483485 10.1074/jbc.M110.123992
44. Miller C. W., Ntambi J. M., Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proceedings of the National Academy of Sciences of the United States of America 1996 93 18 9443 9448 2-s2.0-0029823995 10.1073/pnas.93.18.9443 (Pubitemid 26296627)
45. Gastaldelli A., Harrison S. A., Belfort-Aguilar R., Hardies L. J., Balas B., Schenker S., Cusi K., Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009 50 4 1087 1093 2-s2.0-70350064027 10.1002/hep.23116
46. Neuschwander-Tetri B. A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010 52 2 774 788 2-s2.0-77955690182 10.1002/hep.23719
47. Lomonaco R., Ortiz-Lopez C., Orsak B., Webb A., Hardies J., Darland C., Finch J., Gastaldelli A., Harrison S., Tio F., Cusi K., Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012 55 5 1389 1397 2-s2.0-84859942552 10.1002/hep.25539
48. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
49. Nagai Y., Yonemitsu S., Erion D. M., Iwasaki T., Stark R., Weismann D., Dong J., Zhang D., Jurczak M. J., Löffler M. G., Cresswell J., Yu X. X., Murray S. F., Bhanot S., Monia B. P., Bogan J. S., Samuel V., Shulman G. I., The role of peroxisome proliferator-activated receptor γ coactivator-1 β in the pathogenesis of fructose-induced insulin resistance. Cell Metabolism 2009 9 3 252 264 2-s2.0-60649109153 10.1016/j.cmet.2009.01.011